WPD Pharmaceuticals Inc.

Equities

WBIO

CA92941F1053

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 09:49:31 2022-06-28 am EDT			5-day change	1st Jan Change
0.045 ^CAD	-.--%		-.--%	-.--%

Feb. 05	WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
Feb. 02	WPD Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

February 05, 2024 at 04:20 pm EST

WPD Pharmaceuticals Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was CAD 0.08585 million compared to CAD 0.926229 million a year ago.
For the nine months, net loss was CAD 0.202469 million compared to CAD 2.31 million a year ago.

Latest news about WPD Pharmaceuticals Inc.

WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Feb. 05	CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	Feb. 02	CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	Jan. 30	CI
WPD Pharmaceuticals Inc. announced that it has received CAD 0.3 million in funding	23-06-14	CI
WPD Pharmaceuticals Inc. Provides Update on Research Project Pipeline	23-05-01	CI
WPD Pharmaceuticals Inc. Announces Directorate Appointments	23-05-01	CI
WPD Pharmaceuticals Inc. announced that it expects to receive CAD 0.3 million in funding	23-04-30	CI
WPD Pharmaceuticals Inc. Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy	23-01-17	CI
WPD Pharmaceuticals Announces First Two Sites Initiated in Poland in Clinical Trial of Berubicin in the Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy (WPD-201)	22-12-18	CI
WPD Pharmaceuticals Inc. Announces First Patient Dosed in Phase 1B/2 Clinical Trial of Annamycin	22-12-05	CI
Liam Corcoran Resigns from WPD Pharmaceuticals Inc.'s Board of Directors, Effective December 1, 2022	22-11-24	CI
WPD Pharmaceuticals Inc. announced that it expects to receive PLN 1.7 million in funding	22-09-13	CI
WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences	22-05-16	CI
WPD Pharmaceuticals Inc. Signs Consortium Agreement on EuroNanoMed Project	22-03-07	CI
WPD Pharmaceuticals Inc. Announces Appointment of Romuald Harwas as a Director	22-02-03	CI
WPD Pharmaceuticals Inc. Secures Berubicin Sub-License Rights in Perpetuity	22-02-01	CI
WPD Pharmaceuticals Signs Agreement with NCRD for $6.3 Million Grant for the Development of Liposomal Annamycin, Intended as a Treatment for AML	21-12-16	CI
WPD Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-29	CI
WPD Pharmaceuticals Plans to Go Public in Poland	21-09-02	CI
Wpd Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-30	CI
WPD Pharmaceuticals Plans to Commence Phase Ib/II Study of Berubicin for the Treatment of Glioblastoma in Second Half of 2021	21-06-28	CI
WPD Pharmaceuticals Inc. Joins International Research Consortium	21-06-10	CI
Wpd Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-06-03	CI
WPD Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	21-06-02	CI
WPD Pharmaceuticals Inc. Receives $6.7 Million Grant for Development of Annamycin Drug Candidate	21-05-11	CI

Chart WPD Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors.

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WPD PHARMACEUTICALS INC.	-.--%	3.73M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs